Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

MRKMerck Sharp & Dohme LLCNot started yet

A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)

Lymphoma, Large B-Cell, Diffuse · Diffuse Large B-Cell Lymphoma

2Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 5 insiders sold shares within a month

    Since Aug 13, 2026 · was worth 5, fading over time

    +1.9
Worry score2

Score over time

Stage
Phase 2/3
Patients
470 (planned)
Started
Dec 13, 2026
Main results expected
Mar 13, 2037
Fully finished
Mar 13, 2037
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Part 1A: Number of Participants Who Experience Dose Limiting Toxicity (DLT)

    Measured over: Up to approximately 42 days

  • Part 1A and 1B: Number of Participants Who Experience an Adverse Event (AE)

    Measured over: Up to approximately 53 months

  • Part 1A and 1B: Number of Participants Who Discontinue Study Treatment Due to an AE

    Measured over: Up to approximately 11 months

  • Part 1B: Objective Response Rate (ORR)

    Measured over: Up to approximately 53 months

  • Part 2: Progression Free Survival (PFS)

    Measured over: Up to approximately 53 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT07917754 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT07917754) ↗